



Marksans Pharma Ltd.

2<sup>nd</sup> April, 2019

To,  
National Stock Exchange of India Limited  
Exchange Plaza  
C-1, Block 'G' Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051.  
Scrip Code: **MARKSANS**

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort,  
Mumbai – 400 001.  
Scrip Code: **524404**

**Sub: Amendment to the Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information**

Dear Sir,

In compliance with the SEBI (Prohibition of insider Trading) (Amendment) Regulations, 2018, the Board of directors of the Company has adopted revised "Code of Practices and Procedures For Fair Disclosure of Unpublished Price Sensitive Information" effective from April 1, 2019. The said revised code is attached herewith and is also available on the Company's website at [www.marksanspharma.com](http://www.marksanspharma.com).

You are requested to note the above in your records.

Thanking You.  
Yours faithfully,  
For **Marksans Pharma Limited**

**Harshavardhan Panigrahi**  
Company Secretary & Manager-Legal

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • E-mail: [info@marksanspharma.com](mailto:info@marksanspharma.com)  
[www.marksanspharma.com](http://www.marksanspharma.com)



# Marksans Pharma Ltd.

## Code of Practices and Procedures For

### Fair Disclosure of Unpublished Price Sensitive Information

#### 1. PRELIMINARY

The Board of Directors of Marksans Pharma Limited (“the Company”) has formulated the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (hereinafter called as “Code of Fair Disclosure”).

#### 2. OBJECTIVE

This Code of Fair Disclosure envisages fair disclosure of events and occurrences that could impact price discovery in the market for the Company’s securities and adhering to principles of fair disclosures such as equality of access to information, publication of policies such as those on dividend, inorganic growth pursuits, calls and meetings with analysts, publication of transcripts of such calls and meetings, etc.

#### 3. OVERSEEING AND CO-ORDINATING DISCLOSURE

Company Secretary shall be responsible for prompt public disclosure of unpublished price sensitive information i.e. to Stock Exchanges that would impact price discovery, so as to ensure uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.

In the event of inadvertent selective disclosure of unpublished price sensitive information, prompt action will be taken to ensure such information is generally available.

Unpublished Price Sensitive Information shall be handled on a "need to know" basis i.e. will be disclosed only who need the information to discharge their duty.

#### 4. RESPONDING TO MARKET RUMOURS

Company Secretary of the Company shall in consultation with the Managing Director and Chief Financial Officer of the Company, promptly deal with any query or request for verification of market rumors received from stock exchanges / regulatory bodies.

#### 5. DISCLOSURE / DISSEMINATION OF PRICE SENSITIVE INFORMATION WITH SPECIAL REFERENCE TO ANALYSTS, INSTITUTIONAL INVESTORS

The Chief Financial Officer only shall disclose any information (which will not be unpublished price sensitive information) relating to the Company's Securities to Institutional Investors & Analysts.

All the officials of the Company should follow the guidelines given hereunder while dealing with analysts and institutional investors:-

(i) Sharing of non-public information

The Chief Financial Officer shall provide only public information to the analysts/research persons/large investors like institutions. In case, non-public



# Marksans Pharma Ltd.

information (which will not be unpublished price sensitive information) is proposed to be provided, the same shall be provided only after disclosure to the stock exchanges and dissemination in the company's website.

(ii) Recording of discussion

Chief Financial Officer shall ensure official confirmation and documentation of disclosures made by making transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the official website.

**6. CHIEF INVESTOR RELATIONS OFFICER**

The Board of Directors of the Company has designated the Chief Financial Officer as the Chief Investor Relations Officer under this Code of Fair Disclosure.

**7. FURTHERANCE OF LEGITIMATE PURPOSES IN THE PERFORMANCE OF DUTIES AND DISCHARGE OF LEGAL OBLIGATIONS.**

(i) The Chief Financial Officer only shall disclose Unpublished Price Sensitive Information, if need be, in furtherance of legitimate purposes, performance of duties or discharge of obligations,

(ii) Legitimate purposes shall be identified by the Chief Financial Officer on need-to-know basis which shall include sharing of Unpublished Price Sensitive Information to business partners, collaborators, bankers, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professional or other advisors or consultants, etc. in the ordinary course of business which are needed in the performance of duties and discharge of legal obligations, provided that such sharing of Unpublished Price Sensitive Information shall not be carried out to evade or circumvent the prohibitions contained in the SEBI (Prohibition of Insider Trading) Regulations, 2015 or any amendment thereof.

(iii) The above recipient of the Unpublished Price Sensitive Information shall be deemed to be Insider and accordingly shall comply with the SEBI (Prohibition of Insider Trading) Regulations, 2015 or any amendment thereof and the codes/policies framed thereunder.

Principles of Fair Disclosure for purposes of Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information as set out in Schedule A of SEBI (Prohibition of Insider Trading) Regulations, 2015 annexed hereto as Annexure – 1 forms part of this Code of Fair Disclosure.

The above Code as revised has been approved by the Board of Directors at its meeting held on 8<sup>th</sup> February, 2019 and will come into effect from 1<sup>st</sup> April, 2019.

\*\*\*\*\*



# Marksans Pharma Ltd.

*Annexure-1*

## **SCHEDULE- A**

### Principles of Fair Disclosure for purposes of Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information

- 1) Prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being in order to make such information generally available.
- 2) Uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.
- 3) Designation of a senior officer as a chief investor relations officer to deal with dissemination of information and disclosure of unpublished price sensitive information.
- 4) Prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise to make such information generally available.
- 5) Appropriate and fair response to queries on news reports and requests for verification of market rumors by regulatory authorities.
- 6) Ensuring that information shared with analysts and research personnel is not unpublished price sensitive information.
- 7) Developing best practices to make transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the official website to ensure official confirmation and documentation of disclosures made.
- 8) Handling of all unpublished price sensitive information on a need-to-know basis.

\*\*\*\*\*